Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | MTAP | Q13126 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13090653 | 0.82 | GBA1 (0.49) | GBA1FUCA1S1PR5MTAPBCHE | |
| SCHEMBL500382 | 0.76 | GBA1 (0.58) | GBA1FUCA1S1PR5 | |
| SCHEMBL500383 | 0.76 | GBA1 (0.58) | GBA1FUCA1S1PR5 | |
| SCHEMBL8171730 | 0.76 | FUCA1 (0.53) | FUCA1S1PR5CTSLCTSBCTSK | |
| SCHEMBL7706510 | 0.74 | DRD2 (0.46) | BCHEACHECTSLCTSBCTSK | |
| SCHEMBL4737243 | 0.73 | BCHE (0.48) | BCHEACHECTSLCTSBCTSK | |
| SCHEMBL13201650 | 0.71 | GBA1 (0.46) | GBA1FUCA1S1PR5CCR5ACHE | |
| SCHEMBL2454394 | 0.70 | GBA1 (0.66) | GBA1FUCA1S1PR5 | |
| SCHEMBL403643 | 0.70 | GBA1 (0.66) | GBA1FUCA1S1PR5 | |
| SCHEMBL440211 | 0.70 | GBA1 (0.66) | GBA1FUCA1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128789-A1 | Process for the preparation of substituted pyrrolidine derivatives and intermediates | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | US | claimed |
| US-7230119-B2 | Process for the preparation of substituted pyrrolidine derivatives and intermediates | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230119-B2 | Process for the preparation of substituted pyrrolidine derivatives and intermediates | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060128789-A1 | Process for the preparation of substituted pyrrolidine derivatives and intermediates | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128789-A1 | Process for the preparation of substituted pyrrolidine derivatives and intermediates | PNISR, PNMT, GRHPR | GBA1 4230/4885FUCA1 4070/4885S1PR5 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.